WO2005081716A3 - DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) - Google Patents
DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) Download PDFInfo
- Publication number
- WO2005081716A3 WO2005081716A3 PCT/US2004/039579 US2004039579W WO2005081716A3 WO 2005081716 A3 WO2005081716 A3 WO 2005081716A3 US 2004039579 W US2004039579 W US 2004039579W WO 2005081716 A3 WO2005081716 A3 WO 2005081716A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sars
- cov
- responses
- polypeptides
- acute respiratory
- Prior art date
Links
- 241000315672 SARS coronavirus Species 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 230000001404 mediated effect Effects 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000004044 response Effects 0.000 abstract 2
- 102000004082 Calreticulin Human genes 0.000 abstract 1
- 108090000549 Calreticulin Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 abstract 1
- 101000793651 Homo sapiens Calreticulin Proteins 0.000 abstract 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 108091061960 Naked DNA Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000053922 human CALR Human genes 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52447903P | 2003-11-24 | 2003-11-24 | |
US60/524,479 | 2003-11-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005081716A2 WO2005081716A2 (en) | 2005-09-09 |
WO2005081716A3 true WO2005081716A3 (en) | 2009-04-02 |
Family
ID=34910678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/039579 WO2005081716A2 (en) | 2003-11-24 | 2004-11-24 | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005081716A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
JP5087201B2 (en) | 2000-08-03 | 2012-12-05 | ジョンズ・ホプキンス・ユニバーシティ | Molecular vaccine with endoplasmic reticulum chaperone polypeptide linked to antigen |
AU2002242016A1 (en) | 2001-02-01 | 2002-08-12 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
US9701725B2 (en) | 2003-05-05 | 2017-07-11 | The Johns Hopkins University | Anti-cancer DNA vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
CA2594040A1 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
WO2006095180A2 (en) * | 2005-03-10 | 2006-09-14 | Ultra Biotech Limited | Humananized monoclonal antibodies against sars - associated coronavirus and treatment of patients with sars |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
CN101915848B (en) * | 2010-07-06 | 2013-09-25 | 中国医学科学院病原生物学研究所 | Application of RBD protein in preparation of auxiliary diagnostic agent for SARS patients |
US9884895B2 (en) | 2014-03-20 | 2018-02-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric coronavirus spike proteins |
JP2020534352A (en) | 2017-09-07 | 2020-11-26 | キュー バイオファーマ,インコーポレーテッド | T cell regulatory multimeric polypeptide with conjugation site and how to use it |
US20210046177A1 (en) * | 2018-01-26 | 2021-02-18 | Nantcell, Inc. | Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy |
CN111196857B (en) * | 2020-02-05 | 2023-07-21 | 杭州贤至生物科技有限公司 | Novel coronavirus multi-epitope recombinant antigen and preparation method thereof |
US20230117521A1 (en) * | 2020-03-25 | 2023-04-20 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof |
US20230210978A1 (en) * | 2020-04-02 | 2023-07-06 | Francois Binette | A universal adoptive immunotherapy approach to treat covid-19 and future emerging infectious diseases |
CN111440229B (en) * | 2020-04-13 | 2021-08-03 | 中国人民解放军军事科学院军事医学研究院 | Novel coronavirus T cell epitope and application thereof |
WO2021214248A1 (en) * | 2020-04-23 | 2021-10-28 | F. Hoffmann-La Roche Ag | Corona nucleocapsid antigen for use in antibody-immunoassays |
US20230181720A1 (en) * | 2020-05-18 | 2023-06-15 | The Regents Of Th University Of California | Safe potent single vector platform vaccine against covid-19 |
WO2021248101A1 (en) * | 2020-06-05 | 2021-12-09 | Epicentrx, Inc. | Mono- and multi-valent sars-cov-2 adenoviral vector vaccines and sars-cov-2 immune globulin and methods of use |
CN111978376B (en) * | 2020-06-15 | 2022-02-18 | 江苏安泰生物技术有限公司 | Pharmaceutical composition for preventing and/or treating coronavirus infection, and preparation method and application thereof |
WO2022026921A1 (en) * | 2020-07-30 | 2022-02-03 | Repertoire Immune Medicines, Inc. | Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19 |
TWI839716B (en) * | 2021-05-18 | 2024-04-21 | 法信諾生醫股份有限公司 | Peptide vaccine for virus infection |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002012281A2 (en) * | 2000-08-03 | 2002-02-14 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
-
2004
- 2004-11-24 WO PCT/US2004/039579 patent/WO2005081716A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002012281A2 (en) * | 2000-08-03 | 2002-02-14 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
Non-Patent Citations (2)
Title |
---|
MARRA M. ET AL.: "The Genome sequence of the SARS-associated coronavirus", SCIENCE., vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002288939, DOI: doi:10.1126/science.1085953 * |
RUAN Y. ET AL.: "Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection", LANCET, vol. 361, no. 9371, 24 May 2003 (2003-05-24), pages 1779 - 1785, XP004783474, DOI: doi:10.1016/S0140-6736(03)13414-9 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005081716A2 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005081716A3 (en) | DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV) | |
Hashem et al. | A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model | |
WO2002080851A3 (en) | Chimeric vaccines | |
WO2002012281A3 (en) | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen | |
CN111088283A (en) | mVSV viral vector, viral vector vaccine thereof and mVSV-mediated novel coronary pneumonia vaccine | |
WO2007106476A3 (en) | Compositions and methods for enhancing the immunogenicity of antigens | |
IL189313A0 (en) | Virus-like particles as vaccines for paramyxovirus | |
Fan et al. | Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes | |
MX342639B (en) | High titer recombinant influenza viruses for vaccines and gene therapy. | |
ES2775278T3 (en) | Composition consisting of an antigen linked to a ligand of the TNF superfamily | |
DK1002110T3 (en) | Immune response to HPV antigens induced by compositions comprising an HPV antigen and a stress protein or expression vector capable of expressing these proteins | |
EA200700849A1 (en) | PRIMARY / BOOSTER ANTI-MALARY VACCINE | |
WO2009105152A3 (en) | Virus-like particles as vaccines for paramyxovirus | |
WO2010039224A3 (en) | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines | |
MX2019003682A (en) | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same. | |
Wang et al. | Epitope DNA vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine | |
WO2006071896A3 (en) | Epitope-based sars vaccine | |
WO2005007673A3 (en) | Immunogenic peptides | |
Nanishi et al. | Alum: CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity | |
WO2006110915A3 (en) | Vaccine formulations for leishmania | |
ATE450545T1 (en) | LAWSONIA INTRACELLULARIS SUBUNIT VACCINE | |
AU6683400A (en) | Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat | |
Schulze et al. | A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus | |
Yang et al. | Immune responses to T-cell epitopes of SARS CoV-N protein are enhanced by N immunization with a chimera of lysosome-associated membrane protein | |
ZA200602107B (en) | Piroplasmid vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |